Waltham-based ImmunoGen Raises Additional $5.3 Million in Stock Sale

From New England Tech Wire

Waltham, Mass. -- ImmunoGen, a Waltham-based
biopharmaceutical company that develops targeted anticancer therapeutics,
announced today that the underwriters of its recent public offering of common
stock have exercised their option to purchase 750,000 additional shares of
common stock at a price of $7 per share, raising an additional $5.3 million. The
exercise of the over-allotment option brings the total shares of common stock to
be sold by ImmunoGen in the offering to 5.75 million shares. Net proceeds will
be approximately $38 million.
http://www.immunogen.com/wt/home/home

View Jobs at ImmunoGen